Incyte to buy Vega Therapeutics for up to $2 billion

Incyte is paying up to $2 billion for Vega Therapeutics, a move that gives the Wilmington, Delaware drugmaker a late-stage entry in bleeding disorders and another shot at growth before Jakafi’s patent protection erodes. The deal, announced June 8, was structured with $1.25 billion upfront and as much as $750 million in milestone payments, underscoring how much Incyte is willing to pay for a program that is already deep in the clinic.

The asset at the center of the transaction is VGA039, a monoclonal antibody that targets Protein S and is in Phase 3 development for von Willebrand disease. ClinicalTrials.gov lists the VIVID-6 study of subcutaneous VGA039 in patients with the disorder, with the record last updated April 3, 2026. Star Therapeutics said in April that VGA039 had received U.S. Food and Drug Administration rare pediatric disease and breakthrough therapy designations and described it as a once-monthly, subcutaneously self-administered investigational therapy.

For Incyte, the purchase is about more than one drug. It expands the company’s hematology portfolio into bleeding disorders and fits a wider industry pattern in which larger drugmakers are buying earlier-stage or late-stage science to refill pipelines instead of relying entirely on internal discovery. That logic is especially clear here: analysts have said the transaction could help bridge the revenue gap expected when Jakafi loses patent protection in 2028. Incyte has been preparing for that pressure point for years, and Bill Meury’s first acquisition since becoming chief executive in 2025 signals a more aggressive posture.

The company said it expects the acquisition to close in the third quarter of 2026 and that it anticipates booking an approximately $1.25 billion research and development charge tied to the deal in its third-quarter and full-year results. That accounting hit is the price of buying time, and perhaps buying a future franchise, in a therapeutic area where effective options remain limited.

For Star Therapeutics and its Vega unit, the sale turns a promising program into cash and gives the subsidiary access to a larger commercial platform. For Incyte, it is a bet that a differentiated bleeding-disorder asset can become meaningful if the data continue to hold up. In a biotech market still rewarding specialty assets with clear clinical paths, the deal shows that investors are willing to pay for pipeline certainty, especially in immunology and hematology, where the next blockbusters are increasingly being purchased rather than discovered in-house.